Weekly FDA Roundup: April 11–17, 2026

Seven Class I device actions in three days, including two tied to the same defective syringe component. CDER issues four warning letters to online pharmacies selling controlled substances. A cosmetics lab is cited for using AI to generate compliance documentation without Quality Unit review. Plus a clinical trial disclosure push touching 2,200+ sponsors, new CBER guidance on genome editing safety, and an FDA signal of a possible label expansion for testosterone therapy.

Seven Class I device actions in three days

Device activity from April 14 to 16 was heavy and tilted toward life-critical equipment. Two of the seven events trace back to the same upstream component, which makes the week worse than the headline count suggests.

Anesthesia and ventilation (three events, all respiratory). Draeger issued a Class I correction for its Atlan A350 and A350 XL anesthesia workstations after manufacturing impurities were found to cause piston ventilator failure, with risk of hypoxia, bradycardia, or cardiac arrest if manual ventilation is not initiated quickly. Philips corrected its Trilogy Evo platform ventilators (Evo, Evo O2, EV300, Evo Universal) for inaccurate tidal volume delivery when non-pneumatic nebulizers are attached and a delay in the Obstruction Alarm. Affected units must update to software 1.05.15.00, and non-pneumatic nebulizers must be removed from use with these devices immediately. Percussionaire issued a Class I correction on its Phasitron 5 In-Line Valve (P5-TEE) for a pressure relief valve leak that poses hypoventilation risk, with neonatal and infant patients at greatest exposure.

Implants and catheters (two events). Stryker issued a Class I correction for its TMJ Concepts Patient-Fitted TMJ Reconstruction Prosthesis System after a design discrepancy between the intended screw hole depth and the actual fossa thickness (approximately 2.6 mm versus the designed depth) created a risk of 6 mm screws penetrating the cranial vault. One serious injury has been reported. Merit Medical recalled its 16F Dual-Valved Splittable Sheath Introducer, used across its Centros, ProGuide, and DuraMax chronic dialysis catheter kits, after the sheath was found to fail to split during procedures. Two serious injuries have been reported as of February 2026.

Two Early Alerts, one upstream component. The FDA issued Early Alerts for convenience kits from Medical Action Industries (Halyard Kit-Pack Cath) and Owens & Minor's American Contract Systems (Coronary Angio Pack). Both kits contain the same component at fault: Medline Namic RA Syringes, where the rotating adaptor may unwind during angiographic procedures and cause disconnection, air embolism, or blood loss. Four serious injuries have been reported across the kits so far. Companies that stock, redistribute, or incorporate these convenience kits should confirm whether any inventory includes the affected Medline syringes and follow the remove-and-destroy instructions on the Early Alerts.

Two food recalls worth noting

Loard's Ice Cream (Silver Moon LP, Northern California) recalled all 32 oz paper and 56 oz plastic retail containers of its ice cream after an FDA inspection found the products were distributed without ingredient labels. Undeclared allergens include milk, eggs, multiple tree nuts, peanuts, soy, wheat, and sulfites, plus multiple FDA-regulated color additives. No illnesses reported.

Revival Animal Health recalled its Breeder's Edge Foster Care Canine and Shelter's Choice Canine milk replacers, sold nationwide, due to variable Vitamin D levels. Two cases of rickets have been reported in animals exposed to underdosed product. Excessive Vitamin D raises separate renal risks.

CDER sweeps four online pharmacies in one day

On April 14, the Center for Drug Evaluation and Research issued warning letters to four companies for selling unapproved and misbranded prescription drugs over the internet to U.S. consumers.

Online Rx Medz and Rxgoodusa were each cited for selling controlled substances (oxycodone, alprazolam, tramadol, diazepam, and amphetamines) without requiring a valid prescription. Dry Springs Pharmacy, based in Hong Kong, was cited for the same conduct, with FDA noting that its products may be detained or refused admission at U.S. borders. Beauty of Aztlan LLC was cited separately for selling injectable botulinum toxin products (Botulax 100 units and Innotox 50 units) online without FDA approval, without a prescription requirement, and without adequate directions for use.

This sweep continues the enforcement trajectory from the previous week's GLP-1 letter cluster. CDER has now broadened its internet pharmacy enforcement from peptide sellers into the opioid, benzodiazepine, and stimulant categories.

CGMP letters: AI-generated compliance docs, unapproved drugs, insanitary conditions

Fourteen warning letters posted on April 14, with a heavy concentration in CGMP violations. One pharmaceutical letter carries language worth tracking closely.

Purolea Cosmetics Lab (CDER) was cited for insanitary conditions including insects and filth at its manufacturing facility, marketing unapproved homeopathic drugs intended to treat shingles and genital herpes, and failing to conduct microbiological and identity testing. The notable finding: FDA explicitly called out the firm's use of AI to generate compliance documentation without review by the Quality Unit. That is new enforcement language, and it treats AI-assisted compliance documentation without QU review as its own CGMP failure. Any firm using AI tools to draft batch records, SOPs, or investigation reports should route those outputs through the same Quality Unit review process as manually prepared documents.

Chemco Corporation received a letter for failure to clean shared manufacturing equipment, failure to conduct identity testing on high-risk drug components, distributing an unapproved topical antifungal, and making misleading "FDA registered facility" claims on labeling. Registration does not confer FDA approval, and the agency continues to flag this framing in enforcement actions.

Medical Products Laboratories was cited for inadequate contamination controls in non-sterile drugs, poor process validation, failure to investigate out-of-specification results, and distribution of unapproved OTC topical drugs containing hydroquinone, sodium sulfacetamide, sulfur, and salicylic acid.

On the food side, Barcelona Nut Company was warned for allergen cross-contact failures during oil roasting, inadequate parameters to reduce Salmonella on peanuts, and severe rodent and insect infestation at a facility the FDA described as structurally deficient. Ocean Group Inc. was cited across four processing facilities for insanitary conditions and resident Listeria monocytogenes contaminating ready-to-eat salmon and tuna. Schlechter Farms was cited for widespread bird feces throughout its onion packing shed, inadequate pest control, and missing cleaning documentation. JZ Wholesale received a letter for rodent infestation, improper storage of toxic chemicals adjacent to food product, and failure to register as a food facility with the FDA.

Two food-adjacent letters addressed unapproved drug claims. Half Hill Farm Inc. was warned for marketing Turkey Tail, Chaga, and Red Reishi mushroom extracts with cancer-fighting and herpes-prevention claims, which the FDA classified as unapproved new drug and misbranding violations.

Two additional April 14 letters fell under the Center for Tobacco Products (mohawksmoke.com and Smart Vending Services) for marketing tobacco products without premarket authorization.

Clinical trial disclosure: 2,200+ sponsors on notice

FDA announced on April 13 that on March 30 it had sent reminder messages to more than 2,200 sponsors and researchers linked to more than 3,000 registered clinical trials that appear to lack required results submissions on ClinicalTrials.gov. The agency's own analysis found that 29.6% of studies likely subject to mandatory reporting have no results posted, one year after trial completion being the statutory deadline for most interventional studies of FDA-regulated products.

FDA Commissioner Makary framed this as an ethics issue: "Those sponsoring clinical trials have an ethical obligation to make results public regardless of the data's influence on the company's share price." The March reminders are pre-notices. The formal next step would be Notices of Noncompliance, which can lead to regulatory action.

For supplement and food companies that have run clinical substantiation studies and registered them on ClinicalTrials.gov in the process, this is a direct compliance signal. The obligation to post results applies regardless of whether the outcome was favorable.

FDA signals new indication path for testosterone therapy

Following a December 2025 expert advisory panel, FDA issued a statement on April 16 encouraging holders of approved testosterone replacement therapy (TRT) NDAs to contact the agency by April 30, 2026 about filing for a new indication: low libido in men with idiopathic hypogonadism.

Currently approved TRT products are limited to men with hypogonadism attributable to identified structural or genetic causes. Idiopathic cases (clinically low testosterone with no underlying cause established) have no approved treatment option today. The December 2025 panel found evidence suggesting TRT may be safe and effective for this population.

The April 30 date is when NDA holders should reach out to discuss what data the agency would require for a supplement filing. For companies in the testosterone and men's health categories, this is a credible early signal that a significant label expansion for an established drug class may be in motion.

Gene therapy draft guidance: NGS for off-target editing assessment

CBER published a draft guidance on April 14 with recommendations for using next-generation sequencing (NGS) methods in nonclinical studies to evaluate off-target editing risks and loss of genome integrity in human gene therapy products. The guidance applies to both ex vivo and in vivo products and is intended to support IND and BLA application packages.

Comment deadline: July 14, 2026.

This primarily affects advanced therapy and biologics developers. For suppliers of raw materials or components to gene therapy manufacturers, it may influence downstream specification and testing requirements at the supply chain level.

Also this week

• Non-invasive bone growth stimulators reclassification (CDRH final rule, April 16). Orthopedic device makers should review the classification change for impact on premarket pathway.
• Pharmacy Compounding Advisory Committee meeting on §503A bulk drug substances nominations (notice April 16). Directly tied to the ongoing compounding and peptide enforcement thread.
• Public meeting: increasing access to nonprescription drugs (notice April 15, comments by May 8). Potential Rx-to-OTC switch signals worth tracking for consumer health brands.
• Orphan Drug information collection (notice April 16). Comment window open for orphan drug sponsors.

Deadlines to track

Date	Item
April 30, 2026	TRT NDA holders to contact FDA about the idiopathic hypogonadism indication
May 8, 2026	Comments due: FDA public meeting on increasing access to nonprescription drugs
June 15, 2026	Comments due: UNLOXCYT patent extension; prescription drug importation; orphan drug information collection
July 14, 2026	Comments due: NGS safety assessment for genome editing in gene therapy (CBER draft guidance)

Item count this week (April 11–17)

Total federal items in database for this period: ~48 Warning letters: 14 Class I device actions (recalls + corrections + Early Alerts): 7 Press releases: 3 Draft guidance / guidance: 2 Rules: 4 Notices (administrative): 15+

---

Policy Canary monitors FDA changes for your specific products, by name, by ingredient. Join the pilot program.